Cancer medicines
Alectinib
Alectinib
An oral targeted therapy for ALK-positive non-small cell lung cancer.
Sources checked · Introductory guide
On this page
How it works
It inhibits ALK kinase signaling to reduce cancer cell growth.[3]
Where it is used
Used after surgery or in metastatic disease in selected ALK-positive NSCLC settings.[1]
Key safety points
Monitor liver function, pulse and muscle symptoms. Report new breathlessness, jaundice, severe muscle pain or fainting immediately.[2]
Questions for your care team
- What are my ALK result and liver, muscle-enzyme and pulse monitoring plans?
Sources and scope
Source documents are in English.
Entries summarize and translate linked official public sources. The source-check date records when those sources were checked; it does not indicate a clinician’s review.
- NCI · Alectinib (opens in a new tab)
- MedlinePlus · Alectinib (opens in a new tab)
- NCI Drug Dictionary · Alectinib (opens in a new tab)
General information based on official public sources. This is not a complete list of uses or side effects. Individual treatment decisions require your care team and current source documents. US-source uses do not establish local approval or reimbursement.